NeuroSense's PrimeC Hits Primary Endpoint in ALS Trial with TDP-43 Reduction — NeuroSense Therapeutics

Event summary

NeuroSense's Phase 2b PARADIGM study of PrimeC in ALS met its primary endpoint, showing a statistically significant reduction in TDP-43 levels compared to placebo (p=0.0421).
The effect was sustained and deepened over 18 months, with continuously treated participants maintaining lower TDP-43 levels than the placebo arm at Day 540 (p<0.001).
PrimeC also demonstrated a statistically significant slowing of ALSFRS-R decline at 12 and 18 months (36.5%, p=0.008; 32.8%, p=0.007) and a ~15-month median survival benefit (HR 0.35, p=0.004).
NeuroSense has secured FDA clearance to initiate its global Phase 3 PARAGON study in ALS.

The big picture

NeuroSense's success in reducing TDP-43, a central driver of ALS progression, marks a significant milestone in neurodegenerative disease research. The Phase 2b results position PrimeC as one of the most comprehensively supported therapeutic candidates in ALS, with a unique combination of biomarker engagement and clinical outcomes. The upcoming Phase 3 trial will be critical in determining whether this approach can deliver meaningful long-term benefits for patients.

What we're watching

Clinical Validation: Whether the TDP-43 reduction and survival benefit observed in Phase 2b will translate into confirmatory Phase 3 results.
Regulatory Pathway: The pace at which NeuroSense can advance PrimeC through global regulatory approvals, starting with the FDA-cleared PARAGON study.
Competitive Positioning: How NeuroSense differentiates PrimeC in the ALS therapeutic landscape, given its multi-target mechanism and compelling biomarker data.